Highlights
- •Commercialized fecal microbiota transplant (cFMT) is an effective and safe therapy for recurrent CDI.
- •Cure rates with oral cFMT and colonoscopy were found to be over 80%.
- •There were no serious adverse events reported as a result of cFMT.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Infection, Disease & HealthAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection.JAMA. 2014; 312: 1772-1778https://doi.org/10.1001/jama.2014.13875
- Fecal microbiota transplantation for the treatment of Clostridium difficile infection: a systematic review.J Clin Gastroenterol. 2014; 48: 693-702https://doi.org/10.1097/MCG.0000000000000046
- Commercialized fecal microbiota transplantation provides efficacious treatment of Clostridium difficile infection.Inf Disp. 2018; 50: 864-867https://doi.org/10.1080/23744235.2018.1500709
- Consequences of Clostridium difficile infection: understanding the healthcare burden.Clin Microbiol Infect. 2012; 18: 5-12https://doi.org/10.1111/1469-0691.12064
- The gut microbiota and host health: a new clinical frontier.Gut. 2016; 65: 330-339https://doi.org/10.1136/gutjnl-2015-309990
- Stool transplantation for older patients with Clostridium difficile infection.J Am Geriatr Soc. 2009; 57: 2386https://doi.org/10.1111/j.1532-5415.2009.02600.x
- Colonoscopic versus nasogastric fecal transplantation for the treatment of Clostridium difficile infection: a review and pooled analysis.Infection. 2012; 40: 643-648https://doi.org/10.1007/s15010-012-0307-9
- Relationship of symptom duration and fecal bacteriotherapy in Clostridium difficile infection – pooled data analysis and a systematic review.Scand J Gastroenterol. 2013; 48: 266-273https://doi.org/10.3109/00365521.2012.743585
- Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection.Clin Infect Dis. 2011; 53: 994-1002https://doi.org/10.1093/cid/cir632
Article info
Publication history
Published online: July 20, 2022
Accepted:
June 28,
2022
Received in revised form:
June 24,
2022
Received:
May 22,
2022
Identification
Copyright
© 2022 Australasian College for Infection Prevention and Control. Published by Elsevier B.V. All rights reserved.
